Metubine iodide
Brand names,
Metubine iodide
Analogs
Metubine iodide
Brand Names Mixture
Metubine iodide
Chemical_Formula
C23H31NO7
Metubine iodide
RX_link
http://www.rxlist.com/cgi/generic3/cellcept.htm
Metubine iodide
fda sheet
Metubine iodide
msds (material safety sheet)
Metubine iodide
Synthesis Reference
No information avaliable
Metubine iodide
Molecular Weight
469.955 g/mol
Metubine iodide
Melting Point
No information avaliable
Metubine iodide
H2O Solubility
Slightly soluble (43 mg/mL at pH 7.4)
Metubine iodide
State
Solid
Metubine iodide
LogP
2.424
Metubine iodide
Dosage Forms
Capsule (250mg); Tablet (500 mg); Powder for solution (200 mg/mL constituted)
Metubine iodide
Indication
For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.
Metubine iodide
Pharmacology
Mycophenolate mofetil is a prodrug of mycophenolic acid, an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.
Metubine iodide
Absorption
Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.
Metubine iodide
side effects and Toxicity
Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Metubine iodide
Patient Information
No information avaliable
Metubine iodide
Organisms Affected
Humans and other mammals